Abzena Launches Scientific Advisory Board to Propel Innovation in Biopharma

Abzena's New Scientific Advisory Board: A Step Towards Enhanced Innovation

In an exciting move for the biopharmaceutical field, Abzena, a prominent end-to-end integrated Contract Development and Manufacturing Organization (CDMO) plus Contract Research Organization (CRO), has announced the establishment of its Scientific Advisory Board (SAB). This strategic decision aims to bolster innovation by leveraging the diverse expertise of leading industry professionals deeply entrenched in scientific research and development.

Driving Innovation through Expert Insights

Abzena's commitment to growth and innovation remains steadfast, and the formation of the SAB is a pivotal part of this mission. The board will work in close concert with Abzena's scientific and commercial leaders, offering strategic advice and valuable insights. Matt Stober, CEO of Abzena, articulated the importance of this initiative, noting, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena."

In recent years, Abzena has experienced significant momentum in addressing complex modalities. Initiatives such as Antibody-drug conjugates (ADCs) and bispecifics spotlight the company’s innovative edge. Stober emphasized, "We aim to continue building upon this by offering state-of-the-art technologies and capabilities."

The Vision Behind the Advisory Board

The board is not just a formality; it comprises recognized leaders in biopharma, each contributing extensive experience from various facets of the industry. Joe Principe, CCO of Abzena, expresses his excitement about the new members: “We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry.” Their collective expertise will be crucial in evaluating Abzena's strategies and enhancing the company’s ability to hasten patient access to new medicines.

The Founding Members

1. John Knight, Ph.D. - Founder of JKONSULT, John brings 38 years of experience, specializing in process chemistry and CMC consulting for early-stage developments.

2. Kamal Egodage, Ph.D., MBA - As President of Lasanth Consulting, he has over two decades of experience from major firms like Eli Lilly and Novartis. His insights will be vital in bridging discovery with commercialization.

3. Morris Rosenberg, D.Sc. - With over 25 years in therapeutic agent development, Morris has played pivotal roles in ADC therapies. His experience with Seattle Genetics will guide strategic product development.

4. Scott Rudge, Ph.D. - Co-founder of RMC Pharmaceutical Solutions, Scott has held various senior roles in the industry for over 33 years, making him a powerhouse in product and process development.

5. Steven Sandoval - CEO of Pharmaceutical Technical Solutions, Steven's extensive operational background in biopharmaceuticals will provide crucial oversight in technical advancements.

6. Tatyana Touzova - As Chief Development and Manufacturing Officer at SERA Medicines, Tatyana’s wealth of experience in CMC strategy will enhance Abzena's regulatory and manufacturing operations.

Moving Forward with Purpose

Abzena’s formation of the SAB signals a proactive approach to addressing the challenges in biopharmaceutical development. Their goal is not just to keep pace with innovation but to set the standard for it. By harnessing the insights from this board, Abzena is poised to streamline the development of complex biologics, ensuring that new therapies reach patients efficiently.

The company, headquartered in San Diego with additional facilities in Bristol, PA and Cambridge, UK, aims to continue transforming the biopharmaceutical landscape. With strategic investments from Welsh, Carson, Anderson & Stowe, Abzena is committed to delivering exceptional services that de-risk the development of life-saving medicines.

This advisory board will play a significant role in guiding the next chapter of Abzena's journey, ensuring that they remain at the forefront of biopharmaceutical innovation.

For more information on their initiatives and services, visit abzena.com.